Last reviewed · How we verify

Glycopyrronium MDI 7.2 micrograms — Competitive Intelligence Brief

Glycopyrronium MDI 7.2 micrograms (Glycopyrronium MDI 7.2 micrograms) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Respiratory.

phase 2 Anticholinergic Muscarinic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Glycopyrronium MDI 7.2 micrograms (Glycopyrronium MDI 7.2 micrograms) — Pearl Therapeutics, Inc.. Glycopyrronium is an anticholinergic that works by blocking the action of acetylcholine at muscarinic receptors, leading to bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Glycopyrronium MDI 7.2 micrograms TARGET Glycopyrronium MDI 7.2 micrograms Pearl Therapeutics, Inc. phase 2 Anticholinergic Muscarinic receptor
SOLIFENACIN SUCCINATE SOLIFENACIN SUCCINATE marketed Muscarinic receptors 2004-01-01
DICYCLOMINE DICYCLOMINE marketed Antispasmodic and anticholinergic (antimuscarinic) agent Muscarinic receptors 1950-01-01
Solifenacin plus Tamsulosin Solifenacin plus Tamsulosin Soonchunhyang University Hospital marketed Anticholinergic agent + alpha-1A adrenergic antagonist combination M3 muscarinic receptor; alpha-1A adrenergic receptor
albuterol plus tiotropium albuterol plus tiotropium IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy marketed Combination bronchodilator (SABA + LAMA) Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler Umeclidinium / Vilanterol Dry Powder Inhaler Gary L. Pierce marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glycopyrronium MDI 7.2 micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-mdi-7-2-micrograms. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: